- Home
- / OncBioMune Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
OncBioMune Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2022-04-27
Market Capitalization
$8.7 B
2022-04-27
Revenue
$124.7 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.1K | 77.9K | 24.0 | 505.6K | 567.9K | 124.7K | |||||
| Cost of goods sold | 219.4K | 52.4K | 117.5K | 224.9K | 126.2K | ||||||
| Gross profit | 561.6K | 25.6K | 388.1K | 343.0K | 480.6K | ||||||
| Gross profit margin, % | 71.9% | 32.8% | 60.4% | 385.5% | |||||||
| General and administrative expense | 62.6K | 77.7K | 198.1K | 182.2K | 214.2K | 225.2K | 174.3K | 189.4K | 2.7M | 2.2M | 125.0K |
| Operating expense total | 401.6K | 110.8K | 250.2K | 267.5K | 308.6K | 329.1K | 378.8K | 356.1K | 6.0M | 12.0M | 9.5M |
| Depreciation and amortization | 17.4K | ||||||||||
| EBIT | (565.9K) | (807.6K) | (1.8M) | (2.5M) | (1.8M) | (1.8M) | (5.6M) | (11.6M) | (9.0M) | ||
| EBIT margin, % | -2358008.3% | -2049.6% | -7203.7% | ||||||||
| Interest expense | 22.6K | 45.8K | 16.9M | ||||||||
| Net Income | (952.5K) | (315.9K) | (757.4K) | (990.4K) | (2.0M) | (20.5M) | 6.5M | (9.4M) | (5.5M) | (12.7M) | (30.9M) |
| EPS | 0.0 |